JSE weaker as investors pore over details of Covid-19 vaccine
Enthusiasm that followed Pfizer’s vaccine breakthrough has faded as details about its production and distribution are assessed
11 November 2020 - 11:03
The JSE was firmer on Wednesday, with its global peers mixed as investors digest unclear important details around the Covid-19 vaccine.
The enthusiasm that followed Pfizer’s vaccine breakthrough has faded as details about its production, distribution, performance and capabilities still need to be clarified. With this in mind, investors are aware that it may take months for the vaccine to be available...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.